22nd Century Group (NYSE: XXII) recently received a number of ratings updates from brokerages and research firms:

  • 8/26/2017 – 22nd Century Group was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.50 price target on the stock. According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “
  • 8/25/2017 – 22nd Century Group was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “
  • 8/19/2017 – 22nd Century Group was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $2.25 price target on the stock. According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “
  • 8/18/2017 – 22nd Century Group was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “22nd Century Group, Inc. is a plant biotechnology company focused on decreasing/increasing the level of nicotine in the tobacco plant through genetic engineering and breeding. The Company is focused on development of smoking cessation aid and owns and controls several patents. The company’s products include X-22, a prescription smoking cessation aid, which is a tobacco-based botanical medical product for use as a smoking cessation therapy. 22nd Century Group, Inc. is based in Williamsville, New York. “

Shares of 22nd Century Group Inc (NYSE XXII) traded down 3.51% on Thursday, hitting $2.20. The company’s stock had a trading volume of 1,916,982 shares. 22nd Century Group Inc has a 52 week low of $0.81 and a 52 week high of $2.84. The stock’s 50-day moving average price is $1.90 and its 200-day moving average price is $1.46. The firm’s market cap is $226.07 million.

In other news, VP Michael Robert Moynihan sold 29,532 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $2.00, for a total transaction of $59,064.00. Following the completion of the sale, the vice president now directly owns 917,220 shares in the company, valued at approximately $1,834,440. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Receive News & Ratings for 22nd Century Group Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 22nd Century Group Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.